JP Morgan Chase’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-3
| Closed | -$15 | – | 7716 |
|
|
2025
Q2 | $15 | Buy |
+3
| New | +$9 | ﹤0.01% | 6967 |
|
|
2024
Q3 | – | Sell |
-1
| Closed | -$8 | – | 7669 |
|
|
2024
Q2 | $8 | Hold |
1
| – | – | ﹤0.01% | 7225 |
|
|
2024
Q1 | $22 | Hold |
1
| – | – | ﹤0.01% | 7159 |
|
|
2023
Q4 | $14 | Sell |
1
-304
| -100% | -$3.66K | ﹤0.01% | 7396 |
|
|
2023
Q3 | $6.03K | Sell |
305
-16,113
| -98% | -$694K | ﹤0.01% | 6346 |
|
|
2023
Q2 | $1.26M | Sell |
16,418
-365
| -2% | -$29.5K | ﹤0.01% | 3880 |
|
|
2023
Q1 | $1.59M | Buy |
16,783
+6
| +0% | +$571 | ﹤0.01% | 3704 |
|
|
2022
Q4 | $1.63M | Sell |
16,777
-58
| -0.3% | -$8.41K | ﹤0.01% | 3710 |
|
|
2022
Q3 | $4.34M | Sell |
16,835
-11,288
| -40% | -$3.28M | ﹤0.01% | 2862 |
|
|
2022
Q2 | $5.23M | Buy |
28,123
+6,253
| +29% | +$598K | ﹤0.01% | 2757 |
|
|
2022
Q1 | $2.14M | Sell |
21,870
-2,552
| -10% | -$328K | ﹤0.01% | 3700 |
|
|
2021
Q4 | $3.99M | Sell |
24,422
-61
| -0.2% | -$13.4K | ﹤0.01% | 3254 |
|
|
2021
Q3 | $6.68M | Sell |
24,483
-7,747
| -24% | -$2.37M | ﹤0.01% | 2775 |
|
|
2021
Q2 | $12.8M | Sell |
32,230
-2,853
| -8% | -$1.33M | ﹤0.01% | 2216 |
|
|
2021
Q1 | $18.9M | Buy |
35,083
+17,656
| +101% | +$11M | ﹤0.01% | 1804 |
|
|
2020
Q4 | $6.59M | Buy |
17,427
+5,266
| +43% | +$2.09M | ﹤0.01% | 2573 |
|
|
2020
Q3 | $4.69M | Buy |
12,161
+2,578
| +27% | +$1.14M | ﹤0.01% | 2625 |
|
|
2020
Q2 | $4.71M | Buy |
9,583
+5,703
| +147% | +$2.54M | ﹤0.01% | 2499 |
|
|
2020
Q1 | $1.43M | Buy |
3,880
+2,283
| +143% | +$1.18M | ﹤0.01% | 3191 |
|
|
2019
Q4 | $1.13M | Buy |
1,597
+1,246
| +355% | +$857K | ﹤0.01% | 3761 |
|
|
2019
Q3 | $225K | Buy |
351
+57
| +19% | +$45.2K | ﹤0.01% | 4581 |
|
|
2019
Q2 | $253K | Buy |
294
+79
| +37% | +$54.3K | ﹤0.01% | 4571 |
|
|
2019
Q1 | $124K | Sell |
215
-10
| -4% | -$4.18K | ﹤0.01% | 4818 |
|
|
2018
Q4 | $63K | Buy |
225
+21
| +10% | +$8.3K | ﹤0.01% | 5000 |
|
|
2018
Q3 | $98K | Buy |
204
+25
| +14% | +$10.7K | ﹤0.01% | 4963 |
|
|
2018
Q2 | $81K | Sell |
179
-91
| -34% | -$57.7K | ﹤0.01% | 4911 |
|
|
2018
Q1 | $159K | Buy |
270
+80
| +42% | +$49.9K | ﹤0.01% | 4442 |
|
|
2017
Q4 | $117K | Buy |
190
+189
| +18,900% | +$136K | ﹤0.01% | 4610 |
|
|
2017
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 4915 |
|
|
2017
Q2 | $1K | Sell |
1
-520
| -100% | -$510K | ﹤0.01% | 4891 |
|
|
2017
Q1 | $495K | Sell |
521
-825
| -61% | -$768K | ﹤0.01% | 3710 |
|
|
2016
Q4 | $1.08M | Buy |
+1,346
| New | +$1.21M | ﹤0.01% | 3402 |
|
|
2016
Q3 | – | Sell |
-4
| Closed | -$3.21K | – | 4794 |
|
|
2016
Q2 | $3K | Buy |
+4
| New | +$4.36K | ﹤0.01% | 4555 |
|
|
2016
Q1 | – | Sell |
-3
| Closed | -$3.07K | – | 4931 |
|
|
2015
Q4 | $3K | Buy |
+3
| New | +$4.96K | ﹤0.01% | 4462 |
|
|
2013
Q4 | – | Sell |
-245
| Closed | -$145K | – | 4236 |
|
|
2013
Q3 | $145K | Sell |
245
-341
| -58% | -$154K | ﹤0.01% | 4112 |
|
|
2013
Q2 | $185K | Buy |
+586
| New | +$163K | ﹤0.01% | 4010 |
|
Other funds holding TCRT
TRCT
BTI
JP Morgan Chase's TCRT Position: Q3 2025 in Review
JP Morgan Chase sold out of Alaunos Therapeutics (TCRT) in Q3 2025, closing a stake of 3 shares — an estimated $15 sold.
JP Morgan Chase first reported a position in TCRT in Q2 2013 and held it in 36 quarters. The position peaked at $18.9M in Q1 2021. 26 funds tracked by Wall St. Rank hold TCRT as of Q3 2025.
- JP Morgan Chase reported no remaining Alaunos Therapeutics position as of Q3 2025 after selling out during the quarter.
- JP Morgan Chase sold 3 Alaunos Therapeutics shares in Q3 2025, an estimated $15.
- JP Morgan Chase first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 36 quarters.
- JP Morgan Chase's Alaunos Therapeutics position peaked at $18.9M in Q1 2021.
- 26 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2025.
Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.